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Objective: This study reports the clinical characteristics and outcome of HIV-associated Penicilliummarneffei
infection in northern Vietnam.
Methods: We conducted a retrospective chart review of all patients with laboratory confirmed Penicilliummarneffei
infection admitted to the National Hospital for Tropical Diseases in Hanoi, Vietnam, between July 2006 and
September 2009.
Results: 127 patients with P. marneffei infection were identified. All were HIV-infected; median CD4+ T-cell count
was 24 cells/μl (IQR:12-48); 76% were men. Common clinical features were fever (92.9%), skin lesions (82.6%),
hepatomegaly (61.4%), lymphadenopathy (40.2%), weight loss (59.1%) and cough (49.6%). Concurrent opportunistic
infections were present in 22.0%; half of those had tuberculosis. Initial treatment regimens were: itraconazole or
ketoconazole capsule (77.2%), amphotericin B (20.5%), and fluconazole (1.6%). In-hospital mortality was 12.6% and
showed no significant difference in patients treated with itraconazole (or ketoconazole) and amphotericin B (p= 0.43).
Dyspnea, ascites, and increased LDH level were independent predictors of mortality. No seasonality was observed.
Conclusion: The clinical features, treatments and outcomes of HIV-associated P. marneffei infection in northern
Vietnam are similar to those reported in other endemic regions. Dyspnea was an important predictor of mortality.
More patients were treated with itraconazole than amphotericin B and no significant difference in treatment
outcome was observed. It would be of clinical value to compare the efficacy of oral itraconazole and amphotericin
B in a clinical trial.
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Penicillium marneffei can cause a fatal systemic mycosis in
immunosuppressed patients and is one of theleading cause-
sof mortality in people living with Human Immunodefi-
ciency Virus (HIV) in South-East Asia [1-3]. Penicilliosis
presents primarily as a disseminated disease in HIV-
infected patients with CD4+ T-cell count <100 cells/μL, in-
volving the blood stream, skin, liver, spleen, lymph nodes,
bone marrow, lung and gastrointestinal tract [2,4]. Typical* Correspondence: mlarsson@oucru.org
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reproduction in any medium, provided the orumbilicated skin lesions are present in 70% of patients,
facilitating early empirical antifungal therapy and resulting
in better outcomes [4]. Laboratory diagnosis is made by
microscopy and culture of skin lesions, blood, lymph node,
or other body fluids [3].The majority of patients respond
well to either amphotericin B or itraconazole treatment
[2,4-6]; however no randomized controlled trials have been
conducted to evaluate treatment choices for penicilliosis.Study design
We conducted a retrospective patient chart review of all
patients with a compatible clinical syndrome and culture
confirmed P. marneffei infection admitted to the Na-
tional Hospital for Tropical Diseases (NHTD) in HanoiLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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included: demographics, admission date, clinical charac-
teristics, HIV status, CD4+ T-cell count, laboratory
investigations, concurrent opportunistic infections (OIs),
treatment, and hospital outcome. P. marneffei was cul-
tured from clinical specimens according to standard cul-
ture techniques [7]. For seasonality analysis, we assessed
the number of penicilliosis admissions during dry versus
rainy months in relation to all HIV-related admissions
identified from hospital records. For outcome analysis
three variables were used: 1. Survival including clinical
improvement, defined as regression of symptoms such
as fever, skin lesions, lymphadenopathy, hepatomegaly
and splenomegaly, or resolution; 2. death at hospital dis-
charge; 3. Lost to follow up due to that the patient were
taken home or referred to another health facility and
could not be contacted. We performed univariate and
multivariate logistic regressions using forward stepwise
selection of predictor variables. Statistically significant
results (p < 0.05) from the univariate analysis were
entered into a multivariate logistic regression model
where continuous variables were dichotomized based on
the mean values and after exclusion of correlated vari-
ables. The analysis was performed using Statistics Pack-
age of Social Sciences (SPSS version 19, USA).Results
P. marneffei infection was diagnosed in 127 patients,
42.5% by both blood and skin lesion culture, 29.1% by
blood culture alone, and 28.3% by skin lesion culture
alone. The average age was 32 years (range 21–50); the
majority was male (75.6%), and 81.9% came from pro-
vinces outside of Hanoi in northern Vietnam. The
reported route of HIV infection was intravenous drug use
(IDU) (37.0%), commercial sex (29.9%), husband to wife
(15.7%), combination of IDU and commercial sex (7.9%)
and unknown (9.0%). 29.9% had been on antiretroviral
therapy (ART) prior to the diagnosis of penicilliosis; the
mean duration of ART was 10.8 weeks (SD 18.4).
The clinical and laboratory features are shown in
Table 1 and Table 2. The median CD4+ T-cell count on
admission was 24 cells/μl (IQR: 12–48). Other OIs were
diagnosed (n = 28, 22%) patients; including tuberculosis
(n = 14, 11.0%), Pneumocystis jirovecii pneumonia (PCP)
(n = 6, 4.7%), varicella-zoster virus (n = 4, 3.1%) as well as
toxoplasmosis, cytomegalovirus retinitis and herpes sim-
plex virus type 1 infection all (n = 1, 0.8%). Five patients
also had bacteremia with the following pathogens:
Escherichia coli, Staphylococcus aureus, Streptococcus
pyogenes and Salmonella spp. Six patients were previ-
ously diagnosed and received treatment for penicilliosis;
however, none had started ART. In addition to blood
and skin lesion cultures, there were 9 CSF culturesperformed of which one was positive for P. marneffei
and 11 lymph node aspirate cultures were all negative.
The initial choices of antifungal treatments are listed in
Table 3. Outcome at discharge was clinical improvement
or resolution in 107 (84.2%) patients and death in 16
(12.6%). Nine patients were discharged early due to re-
quest from the family members, or referred to other hos-
pital. Five of them were assessed within a month after
discharge and four patients were lost to follow-up. The
mean duration of treatment in the hospital was 15.5 days
(SD 11). For diseased patients deaths occurred early in
the course of treatment after an average of 6.6 days (SD
10), compared to survivors, who were treated in average
16.7 days (SD 10)(p < 0.001). Among 98 patients receiv-
ing itraconazole or ketoconazole, 85 (86.7%) had an im-
provement; 13 (13.3%) died. By comparison, among 26
patients receiving amphotericin B, 24 (92.3%) had an im-
provement; and two (7.7%) patients died. The mortality
differences between the two treatment groups did not
reach statistical significance (p = 0.43, χ2-test).
Results of the logistic regression are shown in Table 1
for clinical variables and Table 2 for laboratory variables.
Univariate analysis showed significantly higher risk of
death among patients with dyspnea, defined as a com-
bination of subjective sensation of difficulty breathing
and observed tachypnea, ascites, jaundice, splenomegaly
(Table 1), increased levels of alanine transaminase
(AST), bilirubin, lactate dehydrogenase (LDH), white
blood cell count, blood urea, thrombocytopenia and pro-
longed prothromb in time (Table 2). However, in the
multivariate analysis, only dyspnea, ascites and increased
LDH levels remained independent predictors of mortal-
ity. Of the 11 patients that died 6 had dyspnea, none of
them had tuberculosis or Pneumocystis jiroveci. How-
ever, two were diagnosed with sepsis, one Escherichia
coli and one Streptococcus pyogenes. In total 23 patients
had X-ray confirmed lesions of the lungs, 5 of these also
had dyspnea (p = 0.015), 4 had pulmonary tuberculosis
and 2 had Pneumocystis jiroveci, 4 died, of those 2 were
diagnosed with tuberculosis. Of the 5 patients with dys-
pnea and lung lesions one was diagnosed with Pneumo-
cystis jiroveci and none with tuberculosis.
Assessment of seasonality was performed for the year
2007 and 2008. During these two years P.marneffei
accounted for 87 of 793 (11.0%) of all HIV related admis-
sions. The number of penicilliosis admissions was 43 dur-
ing the hot rainy months (May to October) and 44 during
the cooler dry months (November to April). The number
of all HIV-related admissions was 463 during the
rainy months and 330 during the dry months. The
proportion of penicilliosis admissions in relation to
all HIV-related admissions comparing dry versus
rainy season did not show statistically significant dif-
ference (p = 0.07, χ2-test).
Table 1 Clinical features and association with outcome in 127 patients with penicilliosis







P value Odds Ratio 95% Confidence Interval
N (%) N (%) N (%)
Male sex 96 (76%) 12 (75%) 84 (76%) NS
Age Mean 32 (SD 5.5) Mean 32 (SD 5.7) Mean 32 (SD 5.3) NS
Symptoms/Signs N (%) N (%) N (%)
Fever 118 (93%) 16 (100%) 102 (92%) 0.285 1.2 1.1 - 1.2
Skin lesions 105 (83%) 13 (81%) 92 (83%) 0.552 0.9 0.2 – 3.4
Weight loss 75 (59%) 8 (50%) 67 (60%) 0.300 0.7 0.2 – 1.9
Cough 63 (50%) 6 (38%) 57 (51%) 0.222 0.6 0.2 – 1.7
Diarrhoea 34 (27%) 6 (38%) 28 (25%) 0.233 1.8 0.6 – 5.3
Lymphadenopathy 51 (40%) 5 (31%) 46 (41%) 0.310 0.6 0.2 – 2.0
Hepatomegaly 78 (61%) 12 (75%) 66 (59%) 0.180 2.0 0.6 – 6.7
Splenomegaly 46 (37%) 10 (62%) 37 (33%) 0.025 3.3 1.1 – 9.9
Ascites 29 (23%) 7 (44%) 22 (20%) 0.040 0.048* 3.1 4.42* 1.1 – 9.4 1.01-19.32*
Jaundice 17 (15%) 5 (31%) 12 (11%) 0.041 3.8 1.1 – 12.6
Dyspnoea 11 (9%) 6 (38%) 5 (4%) 0.000 .013* 12.7 9.50* 3.3 – 49.2 1.62-55.68*
* Multiple regressionanalysis; SD. standard deviation.
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Penicilliosis accounted for 11% of all HIV-related admis-
sions at NHTD in Hanoi during 2007 and 2008 which is
higher than the 4.4% reported from the major referral
hospital for infectious diseases in Ho Chi Minh City,Table 2 Laboratory test results of 127 patients with penicillio
Laboratory findings All N= 127 (100%) Fatal Cases N=
Mean (SD) N Mean (SD
Hemoglobin (g/L) 92 (26) 126 95 (24)
AST(U/L) 189 (183) 125 285 (238
ALT(U/L) 82 (81) 125 78 (71)
Albumin (g/L) 33.9 (8.4) 101 30.2 (8.3)
Total bilirubin (μmol/L) 37.5 (54.4) 85 49 (57)
LDH (U/L) 1104 (1378) 92 2501 (266
CD4+ T-cell count (cells/μL) 36.9 (37.6) 114 31 (32)
White blood cell count(cells/μL) 5777 (4063) 105 8667 (65
Platelets (cells/μL) 134 (100) 126 91 (81)
Prothrombin time 74.4 (28.1) 54 42 (19)
Creatinine (μmol/L) 95.2 (69.4) 120 103 (41)
Urea(mmol/L) 5.96 (3.32) 123 8.2 (4.0)
Fatal Cases N=16 (13%) Non Fatal
N = 111 (8
Positive blood culture 16 (100%) 75 (68%
Positive skin culture 8 (50%) 82 (74%
* Significant in binary multiple regression where LDH was dichotomized based on t
SD, standard deviation.southern Vietnam [4]. However as NHTD is a specia-
lized tertiary hospital, and most (82%) of the cases were
referred, and because other epidemiological data were
lacking, it cannot be concluded that there is a difference
in disease prevalence between northern and southernsis
16 (13%) Non Fatal Cases N=111 (87%) P value
) N Mean (SD) N
16 92 (26) 110 0.666
) 16 175 (170) 109 0.024
16 82 (83) 109 0.841
16 34.6 (8.3) 85 0.055
16 35 (54) 109 .410
2) 15 832 (714) 77 0.000
0.049*
10 38 (38) 104 0.401
4) 9 5506 (369) 96 0.025
16 141 (101) 110 0.037
10 82 (25) 44 0.000
16 94 (73) 104 0.477
16 5.6 (3.1) 107 0.003
Cases
7%)
P value Odds Ratio 95% Confidence Interval
) .003 1.2 1.1 – 1.3
) 0.075 0.4 0.1 – 1.0
he mean value 1104 with 22 above and 70 below (OR 3.81 95% CI: 1.0-14.4),
Table 3 Initial antifungal treatment and association with outcomes among126* patients with penicilliosis
All Fatal Cases Non Fatal Cases Pvalue Odds Ratio 95% Confidence Interval
N= 126 N=16 N=110
(100%) (13%) (87%)
N (%) N (%) N (%)
Itraconazole 77 (61%) 11 (69%) 66 (60%) 0.222 1.8 0.6 – 5.5
Ketoconazole 4 (3%) 1 (6%) 3 (3%) 0.420 2.4 0.2 – 24.6
Amphotericin B 26 (21%) 2 (13%) 24 (22%) 0.35 0.5 1.1 – 2.6
Fluconazole 2 (2%) 1 (6%) 1 (1%) 0.237 7.3 0.4 – 123.5
Itraconazole or Ketoconazole** 17 (13%) 1 (6%) 16 (15%) 0.330 0.4 0.05 – 3.2
*Treatment data lacking for one patient.
**Itraconazoleand ketoconazole were used interchangeably based on availability.
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losis are consistent with other studies including pro-
found immunosuppression (median CD4+ T-cell count:
24 cells/μl) and high rate of co-infections with other
opportunistic pathogens [2,4,6]. One third of the
patients were already on ART for in average 10 days,
this indicates that many patients had an ongoing P.
marneffei infection that was not revealed before initi-
ation of ART, but was probably unmasked by immune
reconstitution inflammatory syndrome (IRIS) after initi-
ation of ART, this has earlier been reported in a few
case studies [8,9].
In our study the presence of dyspnea, ascites, and high
LDH levels on admission independently predicted hos-
pital mortality. Of the six patients that had dyspnea and
died no one had tuberculosis or Pneumocystis jiroveci
diagnosis, however two had septicemia. This may indi-
cate that pulmonary involvement (i.e. P. marneffei pneu-
monia) drives disease severity or that the disease severity
result in pulmonary lesions. This is consistent with a
prior study showing that high respiratory rates and dys-
pnea among penicilliosis patients predicted poor hospital
outcome [4]. Of the 11 patients with dyspnea 5 also had
lung lesions, of these one was diagnosed with Pneumo-
cystis jiroveci and non with tuberculosis. Lung involve-
ment of P. marneffei has been shown in Taiwan where it
was found to be the most common cause of cavities in
the lungs of immunosuppressed HIV infected patients
[10]. The majority of patients with dyspnea did not have
lung lesions, hence the dyspnea might be due to the
severe condition with multi-organ involvement and
acute respiratory distress syndrome (ARDS). It should
be noted that there could be some under diagnosis of
tuberculosis due to the poor sensitivity for sputum
microcopy and culture in immunosuppressed individuals
as well as for Pneumocystis jiroveci as microscopy of
sputum, obtained by nebulizer or bronchoscopy, is not
routinely performed.
Typical skin lesions were present in 80% of patients in
this study. The pathogenesis and prognosis of skininvolvement is poorly understood. Although a previous
study showed that presence of typical skin lesions facili-
tates early initiation of empirical antifungal treatment
and results in better outcome [4], it is unclear whether
skin involvement itself is a prognostic marker. In the ab-
sence of skin lesions, the differential diagnoses for an
AIDS-associated febrile illness with reticuloendothelial
system involvement are broad and include: Mycobacter-
ium tuberculosis, Mycobacterium Avium Complex, histo-
plasmosis and cryptococcosis among others [11]. This
poses a major challenge in diagnosis and treatment,
especially in areas with poor access to blood culture and
other diagnostic laboratory. Penicilliosis should be con-
sidered in all severely immunosuppressed HIV patients
with one or more of the common presentations, skin
lesions, lymphadenopathy, hepatomegaly, splenomegaly,
ascites, jaundice and dyspnoea, who have been in
P. marneffei endemic areas, and empirical antifungal
treatment in very ill patients may be indicated.
In this study 22% of the patients had a concurrent OI;
of whom half had tuberculosis. Hence, multiple OIs, par-
ticularly pulmonary tuberculosis, need to be considered.
Tuberculosis and penicilliosis co-infection poses a major
therapeutic dilemma in resource-poor settings as rifam-
picin is a potent P450 inducer and markedly reduces
itraconazole concentrations [12] Amphotericin B is
recommended for patients with concurrent tuberculosis
treatment. An alternative tuberculosis drug rifabutin is
not available in most penicilliosis endemic areas.
The WHO recommended treatment for severe penicil-
liosis, amphotericin B, was only given to 20.5% of
patients. The majority (77.2%) was treated with either
itraconazole or ketoconazole. Although itraconazole is a
recommended alternative treatment for mild to moder-
ate disease or when amphotericin B is unavailable [13],
in Vietnam both mild and severe cases are commonly
treated with oral itraconazole because amphotericin B is
often not available or is too expensive. In our study there
was no significant difference between itraconazole and
amphotericin B in treatment outcome. So far no
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ducted to compare the efficacy of different antifungal
treatment regimens for penicilliosis.
Compared to northern Thailand and southern
Vietnam where cases peak in the rainy season [4],
seasonality was not observed in our cohort. It should be
noted that our small sample size and short time frame
does not enable any conclusive results about seasonality.
However, the cool and dry season in northern Vietnam
is often damp with high humidity which might have an
impact on the reservoirs of P. marneffei.
This study shows that penicilliosis in northern
Vietnam presents with similar clinical characteristics as
in other endemic areas, and that dyspnea is an import-
ant predictor of mortality. It is common practice to treat
patients with oral itraconazole rather than amphotericin
B, and no significant difference in treatment outcome
was observed. It would be of clinical value to compare
the efficacy of oral itraconazole and amphotericin B in a
clinical trial to develop evidenced based guidelines.
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